9 REFERÊNCIAS - dbd.puc-rio.br · Med. Vet. Entomol. , v.14, p. 109-122, 2001. ... Brasileira de...

107

9 REFERÊNCIAS

1.0 Alexander, B. Sampling. Med. Vet. Entomol., v.14, p. 109-122, 2001.

1.1 Antunes CM, Mayrink W, Magalhaes PA, Costa CA, Melo MN, Dias M, Michalick MS,

Williams P, Lima AO, Vieira JB, et al.. Int J Epidemiol. 1986 Dec;15(4):572-80.

1.2 lvar J, Laguna F, Lopez-Velez R, Soriano V, Montilla P, Gonzalez-Lahoz JM. J Infect.

1994 May;28(3):255-9.

1.3 Dietze R, Barros GB, Teixeira L, Harris J, Michelson K, Falqueto A, Corey R.. Clin

Infect Dis. 1997 Nov;25(5):1240-2.

1.4 Looker DL, Berens RL, Marr JJ. Mol Biochem Parasitol. 1983 Sep;9(1):15-28.

1.5 Nelso, D.L., Cox, M.M. (2005), Lehninger, Principles of Biochemistry 4 th ed., W. H.

Freeman.

1.6 Girgis, N. S.; Pedersen, E. B.; Synthesis 1982, 6, 480; Fu, R.; Xu, X.; Dang, Q.; Bai,

X.; J. Org. Chem. 2005, 70, 10810.

1.7 Antunes LMG, Darin JDC, Bianchi MLP. Protective effects of vitamin C against

cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependent

study. Pharmacol Res 2000; 41(4):405-11

1.8 Camargo SMR, Francescato HDC, Lavrador MAS, Bianchi MLP. Oral administration

of sodium selenite minimizes cisplatin toxicity on proximal tubules of rats. Biol Trace

Elem Res 2001; 83(3):251-62.

1.9 Bikramjit Raychaudhury, Shouvik Banerjee, Shreedhara Gupta, Ran Vir Singh, and

Salil C. Datta, Acta Tropica, 2005, July; 1: 1-8

1.10 Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 91(5): 625-633, Sep./Oct. 1996

1.11 Shi W, Schramm VL, Almo SC. Nucleoside hydrolase from Leishmania major.

Cloning, expression, catalytic properties, transition state inhibitors, and the 2.5-a

crystal structure. J Biol Chem. 1999 Jul 23;274(30):21114-20.

1.12 Tanner CE. Immunobiology of visceral leishmaniasis.

Clin Immunol Immunopathol. 1996 Feb;78(2):105-11. Review. No abstract available.

DBD

PUC-Rio - Certificação Digital Nº 0114364/CA

108

1.13 Schmidt G, Walter RD, Konigk E. A purine nucleoside hydrolase from

Trypanosoma gambiense, purification and properties.Tropenmed Parasitol. 1975

Mar;26(1):19-26.

1.14 Simon L. Croft and Graham H. Coombs. Leishmaniasis- current chemotherapy and

recente advances in the search for novel drugs. Trends in Parasitology. 2003 Nov.

v.19 n°11.

3.0 MONTGOMERY, J. A. ; THOMSON, J.R.; SCHABEL, F.M. Cancer Res, 1959, 19,

435 – 437.

3.1 ACHESON, R. M, An introduction to the Chemistry of Heterocyclic Compound. 3ed –

Jonh Wiley & Sons Inc, New York, 1971 , 419 – 20.

3.2 BROWN, D.J. ET AL. Fused Pyrmidines, Purines – Part II, Jonh Wiley & Sons Inc.

New York, 1971, 1- 28.

3.3 KATRITZKY, A. R. ; REES, C.W. Comprehensive Heterocyclic Chemistry – the

structure Reactions, Synthesis ans Uses of Heterocyclic .Compounds, Part 4a, 1ed,

Pergason Press, New York, 1984, 5, 501 – 597 .

3.4 ALBERT, A. ; Heterocyclic Chemistry, an Introduction. Athlone Press, 1968, 251 –

253 .

3.5 FIELD, A. K.; DAVIES M.E.; DEWITT, C.; PERRY, H.C.; LIOU, R.;

GERMESHAWSEN, J. KARKAS, J.D.; ASHTON, W.T. ; JONSTON, D.B.R.; TOLMAN,

R.L. Proc. Natl. Acad. Sci. USA. 1983, 80, 4139 – 4143 .

3.6 CHU, C.K. ; BEACH, J.W. ,JEON, L.S.; CHOI, B.G.; COMER, F.I. ; ALVES, A.J;

SCINEZI, R.F. J. Org Chem. 1991, 56, 6503 – 6505 .

3.17 BOLON, P.J.; WANG, P.Y.; CHU, C.K.; GOSSELIN, G. ; BOUDOUM V. ; PIERA, C.

; MATHE, C. ; IMBACH, J.L.; FARAJ, A. ; et al. Biorg.Med.Chem.Lett. 1996, 6(14) 1657 –

1662, Chem Abst. 1996, 125, 211862v .

3.18 LEONARD, N.J.;FUJII, T.J. Am. Soc., 1963, 3719.

3.19 MONTGOMERY, J;.A.; THOMAS, H.J.J.Org, 1996, 30, 3235-3236.

3.20 TSUKARA, M.; HIROSAWA, T.; KISHINE, S.; J. Plant. Physiol. 1996, 149(1/2) 157

– 162 .

3.21 ZUNIGA – AGUILAR, J.J.; LOPES, I. ; GOMES, A.; VASQUEZ – RAMOS, J.M.

Seed Sic.Res. 1995, 5(4), 219-226, Chem. Abst., 1996, 124, 198236b.

3.22 WANG, X. ; ZHAO, Q. ; LIU, C. ; WANG, D. ; XI, Y. Huaxi Yaoxue Zazhi. 1997,

12(1), 1 – 3, Chem. Abst., 1997, 126, 287631k.

DBD


109

3.23 KONG, S.L.; MARZIAH, M.;. NORLELA,K. ; Proc. Malasys. Biochem. Soc. Conf.

1994, 19 th, 116-117, Chem Abs., 1994, 124, 226797f.

3.25 HISHINUMA, M. ; MAMOTO, K. OGUMA, T. ; MORITANI, N. Patente Japan Kokai

7.751.394, 1977, Chem. Abst. 1977, 87: 135309g.

3.26 HULL, R.J. Chem. Soc, 1958, 2746-2791.

3.27 NOELL, W.; ROBINS, R.K. J. Am Chem Soc, 1959, 81, 5997-6007.

3.28 SENG, W.H.; HUESHI, Y.S.; WU, W.L. Husue Pao, 1977, 9(1), 112, Chem Abst,

1978, 121111n

3.29 MIKSTAIS, U. ; Patente S.U. 857.137, 1981, Chem Abst., 1982, 98, 6483p.

4.0 ROSENBERG, B.; VANCAMP, L.; TROSKO, J.F.; MANSOUR, V.H. Nature, London,

[s.n.], 1969, v.222, p. 385-6.

4.1 KRAKOFF, I.H. Platinum and Other Metal Coordenation Compounds in Cancer

Chemotherapy: Clinical Aplications of Platinum Complexes; Nicoline, M., ED. Boston:

Martinus N. Publishing, 1988, p.351.

4.2 KRAKOFF, I.H. Cancer Treat. Resp., 63, 1623, 1979.

4.3 Rosenberg B. Fundamental studies with cisplatin. Cancer 1985; 55(15): 2303-15.

4.4 Jones TW, Chopra S, Kaufman JS, Flamenbaun W, Trump B. Cis-

diamminedichloroplatinum(II) induced renal failure in the rat. Correlation of

strutuctural and funcional alterations. Lab Invest 1985; 52(2):363-74.

4.5 Choie DD, Longnecker DS, Del Campo A. Acute and chronic cisplatin nephropathy in

rats. Lab Invest 1981; 44(5):397-402.

4.6 Klahr S. Oxygen radicals and renal diseases. Miner Electrolyte Metab

1997;23(3):140-3.

4.7 Volland, J.F. et al. J. Med. Chemistry, 1987, v.30, p.716-719.

4.8 McKEAGE, M. J. Brit J. Cancer.1991, 64, 788 ( procurar editor).

4.9 NAVARRO- RANNINGER, C; LOPEZ-SOLERA, I; PEREZ, J M.; MASAGUER, J. R.;

ALONSO, C. Appl. Organometal Chem., 1993, 7, 57.

4.10 CLETON, F.J.. Oxford Textbook of Oncology Vol 1, ed. Peckham, M., Pinedo,

H.M., Veronesi, H.: Oxford University Press, 1995. p. 445-453.

4.11 MACHADO, A. E. D.; Quim. Nova, 2000, 23, 237.

4.12 OLIVEIRA, R.B.; ALVES, R.J.; Quim. Nova, 2000, 25, 976.

4.13 Douglas X. West and Anthiny E. liberta Coordination Chemistry Reviews, 1993,

123, 49-71.

DBD


110

4.14 W. C. Kaska, C. Carrans, J. Michalowski, J. Jackson and W. Levinson, Bioinorg.

Chem. 1978, 8,225.

4.15 D.L. Klayman, J. E. Bartosevich, T.S. Griffith, C.J. Mason and J.P. Scovill, J. Med.

Chem. 1979, 22, 885. (b) J.Med.Chem. 1979, 22,1367.

4.16 In press, Tiekink, E.R.T. Critical Rew. In OncoloGy/ Hematology 2002. (b) smith,

K.A; Raionone, S. e outros Metal-Based Drugs 1998, 5: 295-304.

4.17 Rosenberg, B.; Van Camp, L.; Krigas, T. Nature 1965, 205, 698.

4.18 Rosenberg, B.; Van Camp, L.; Trosko, J. E.;. Mansour, V. H. Mature 1969, 222,

385.

4.19 SALMONN, S.E. Farmacologia Básicas & Clícnicas, Katzung, B.G., ed.; Rio de

Janeiro: Guanabara Koogan S.A, 1998, p. 629-655.

4.20 HAHN, W.C.; WEINBERG, R.A.; Nat. Rev. Cancer, 2002, 2, 331.

4.21 TAKEDA, M.; KOIDE, H.; JUNG, K.Y.; ENDOU, H. Intranephon Distribution of

Glycine-Amidinotrasnderase Activity in Rats. Ren. Physiol. Bioch., 1992, V.15(3-4),

p.113-118.

4.22 DU VIGNEAUD, V.; COHN, M.; CHLANDLER, J. P.; SCHENECK, J. R.;

SIMMONDS, S. J. Biol. Chem., 1941,140, 625.

4.23 FUJIOKA, M.; TAKATA, Y.; GOMI, T; Arch. Biochem. Biophys., 1991, 285, 181-

186.

4.24 MUDD, S. H.; POOLE, J. R. Metalbol. Clin. Exp., 24, 721-735, 1975.

4.25 STOCKLER, S.; HANEFELD, F.; FRAHM, J. The Lancet, 1996, vol. 348, p. 789-

790.

4.26 FELCMAN, J.; MIRANDA, J. L. . Guanidino-Carboxylate Interactions In Mixed

Complexes Of Copper(II) And Zin(II) Of Biological Importance.. In: Fourth European

Biological Inorganic Chemistry Conference, 1998. Book of Abstracts. Sevilha,

Espanha. v. 1. p. 120-120.

4.27 FELCMAN, J. ; MIRANDA, J. L. Ligand-ligand Interactions of Biological Importance

in Copper(II) Mixed Complexes of Guanidinoacetic Acid. In: 37th IUPAC Congress,

1999, Berlin. Abstracts. Berlin :Sociedade Alemã de Química, 1999. v. 2. p. 567-

567.FELCMAN, J. ; MIRANDA, J. L. . Complexos ternários de Co(II) e ácido

guanidoacético de importância biológica. In: 23a. Reunião Anual da Sociedade

Brasileira de Química, 2000, Poços de Caldas. Livro de Resumos da 23a. Reunião

ANual da SBQ. São Paulo : Sociedade Brasileira de Química, 2000. v. 1. p. QI022-

QI022.

DBD


111

4.29 MIRANDA, J. L; FELCMAN, J. ; SOTO, C. T. . Study Of Cr(III), Zn(II) And Ni(II)

Guanidinoacetic Complexes. In: IX Brazilian Meeting on Inorganic Chemistry, 1998.

Abstracts. Angra dos Reis, RJ, Brasil. v. 1. p. 169-170.

4.30 FELCMAN, J. ; MIRANDA, J. L. . Um modelo de como o ácido guanidoacético se

liga a enzima guanidinometiltransferase. In: 24a. Reunião Anual da SBQ, 2001,

poços de Caldas. Livro de Resumos da 24a reunião Anual da SBQ. São Paulo :

Sociedade Brasileira de Química, 2001. v. 1. p. QI061-QI061.

4.31 SZYFMAN, N. W. ; FELCMAN, J. . Estudo de Complexos Mistos do ïon Vanadila e

Ácidos guanidoacético, Aspartico, Glutâmico e Glicina. In: 25a.

4.32 Reunião Anual da SBQ, 2002, Poços de Caldas. Livro de Resumos da 25a.

Reunião Anual da SBQ, 2002. v. 1. p. QI066-QI066.

4.33 MIRANDA, J. L.; FELCMAN, J. ; WARDELL, J. L. ; SKAKLE, J. . Synthesis and X-

Ray Analysis of the First Dimeric Copper (II) Complex of Guanidino Acetic Acid. In: XI

Brazilian Meetingo on Inorganic Chemistry, 2002, Ouro Preto. Livro de resumos,

2002. v. 1. p. 125-125.

4.34 VERSIANE, O. ; RODRIGUES, B. L. ; MIRANDA, J. L. ; FELCMAN, J. A

Methylenic Group Binds Guanidinoacetic Acid to Glycine and Serine in Two Novel

Copper (II) Complexes: Synthesis, X-Ray-Structure and Spectroscopic

Characterization.. In: 12th International Conference on Biological Inorganic

Chemistry, 2005, Ann Harbour. CD, 2005.

4.35 SALMONN, S.E. Farmacologia Básicas & Clícnicas, Katzung, B.G., ed.; Rio de

Janeiro: Guanabara Koogan S.A, 1998, p. 629-655.

4.36 HAHN, W.C.; WEINBERG, R.A.; Nat. Rev. Cancer, 2002, 2, 331.

5.0 Vogel. A.1989. Textbook of quantitative chemical analysis, 5th ed.New York:

Longman and John Wiley and Sons. 387.

6.0 Figueroa-Villar JD FigueroaVillar JD Villar JDF Figueroa D ; MOTTA, M. A. .

Synthesis of 6-Alkyl- and Arylamino-9-(tetrahydro-2-pyranyl)purines via 6-

Methylsulfonylpurine.. Nucleosides, Nucleotides & Nucleic Acids, USA, v. 19, n. 5&6, p.

1005-1015, 2000.

6.1 SILVERSTEIN, R.M.; BASSLER, G.C.; MORRIL, T.C. Spectrmetric Identification of

Organic Compounds, 5 ed., Jonh Willey & Sons, Inc., New York, 1991.

6.2 Ferreira Victor; Cunha Anna; Paixão Menezes; Cecília Maria; Cloreto isocianúrico:

Aspectos Gerais em Síntese, Química Nova, Vol 29, Nr 3, 520-527, 2006.

DBD


112

ANEXO A

Análise termogravimétrica obtida no equipamento Perkin- Elmer TGA7-

Scanning Rate: 5.0 C/min.

1 A - Composto I

2 A - Composto II

DBD


113

3 A – Composto III

4 A – Composto IV

DBD


114

5 A – Complexo 1

6 A – Complexo 2

DBD


115

7 A – Complexo 3

8 A – Complexo 4

DBD


116

ANEXO B

Espectro de infravermelho obtidos com Espectrometro de Infravermelho Perkin

Elmer FT-IR 2000. Parac a região de 4000 a 370 cm-1 foram utilizadas pastilhas de KBr,

e para região de 570 a 30 cm-1, pastilhas de polietileno.

1 B –Cisplatina

Espectro de IR obtida com pastilha de Kr

706.70

797.85

1034.16

1300.10

1374.46

1412.30

1545.36

1629.61

1659.83

2363.54

2593.13

2926.39

3204.94

3286.03 26

28

30

32

34

36

38

40

42

44

46

48

50

52

54

56

58

60

%T

rans

mitt

ance

500 1000 1500 2000 2500 3000 3500 4000

Wavenumbers (cm-1)

DBD


117

2 B –Cisplatina

Espectro de IR obtida com pastilha de polietileno

85.77

100.54

131.59

197.15

256.07

279.80

319.97

417.95440.90

509.56540.06

70

72

74

76

78

80

82

84

86

88

90

92

94

96

98%

Tra

nsm

ittan

ce

100 200 300 400 500 600 700

Wavenumbers (cm-1)

DBD


118

3 B - 6-Mercaptopurina

Espectro de IR obtida com pastilha de KBr

4 B- 6-Metilsulfonilpurina


602.60

644.10

853.12

931.49

969.35

1141.61

1243.24

1320.15

1381.72

1435.19

1570.58

1656.21

1760.19

2361.50

2555.74

2706.25

2934.71

3104.26

3324.97 30

35

40

45

50

55

60

65

70%

Tra

nsm

ittan

ce

1000 2000 3000 4000

Wavenumbers (cm-1)

526.90

635.84

759.76

943.61

1135.81

1219.99

1317.24

1387.49

1566.28

1676.582364.11

2662.04

2774.94

2928.68

3008.12

3128.07

3447.03

55

60

65

70

75

80

85

90

95

100

%T

rans

mitt

ance

1000 2000 3000 4000 Wavenumbers (cm-1)

DBD


119

5 B - Composto I

Espectro de IR obtida com pastilha de KBr.

6 B - Composto I


86.11

122.94

168.23

195.29

227.21

323.19

360.48

409.82

439.94

480.79

590.92

601.43

677.20

55

60

65

70

75

80

85

90

95

100

%T

rans

mitt

ance

100 200 300 400 500 600 700 Wavenumbers (cm-1)

598.94

706.12

784.14

943.77

1080.27

1226.44

1419.64

1488.121582.50

1643.92

3124.57

45

50

55

60

65

70

75

80

85

90

95

100

%T

rans

mitt

ance

1000 2000 3000 4000 Wavenumbers (cm-1)

DBD


120

7 B - Composto II


8 B - Composto II

Espectro de IR obtida com pastilha de poliestileno.

567.71

643.34

776.45

788.71

885.51

949.79

1048.53

1200.841411.58

1469.10

1508.32

1606.81

1660.54

2363.30

2810.87

2964.463054.92

3402.86

3501.67

30

35

40

45

50

55

60

65%

Tra

nsm

ittan

ce

1000 2000 3000 4000 Wavenumbers (cm-1)

90.08

151.49

193.53

245.73

279.84327.74

346.66368.05

425.37

499.25512.25

564.33573.61

612.95

643.97

673.57

704.75

55

60

65

70

75

80

85

90

95

100

%T

rans

mitt

ance

100 200 300 400 500 600 700 Wavenumbers (cm-1)

DBD


121

9 B – Composto III


10 B – Composto III


503.71

662.40

778.09

820.58

879.26

924.75

981.84

1151.09

1220.26

1381.77

1463.53

1510.17

1612.20

1664.50

1840.03

1876.14

2001.70

2360.22

2914.80

2997.09

3097.55

3236.253742.74

70

75

80

85

90

95

100

%T

rans

mitt

ance

1000 2000 3000 4000 Wavenumbers (cm-1)

67.27

100.00

136.83180.08

226.96

279.72

339.51

409.04

448.52

482.25

490.71

529.32

552.18

597.52

616.54

640.22

698.41

60

65

70

75

80

85

90

95

100

105

%T

rans

mitt

ance

100 200 300 400 500 600 700 Wavenumbers (cm-1)

DBD


122

11 B – Composto IV


12 B – Composto IV


536.35

776.80

904.05

1053.92

1127.68

1209.32

1335.08

1396.72

1455.29

1490.281597.16

1652.70

1723.04

2780.78

3026.96

3113.96

55

60

65

70

75

80

85

90

95

100

%T

rans

mitt

ance

1000 2000 3000 4000 Wavenumbers (cm-1)

56.58

121.38

138.46

150.73

177.57

195.10

224.41

266.12

279.40

302.86

326.12

344.93

407.96

452.24

490.76

523.13

559.66

598.29

639.10

673.73

80

82

84

86

88

90

92

94

96

98

100

102

104

%T

rans

mitt

ance

100 200 300 400 500 600 700 Wavenumbers (cm-1)

DBD


123

13 B – Complexo 1


14 B – Complexo 1

Espectro de IR obtida com pastilha de polietileno .

556.73

920.06

1042.72

1099.001141.37

1235.16

1340.78

1403.21

1583.94

2366.23

2824.49

2931.35

3098.33

3193.34

3392.21

15

20

25

30

35

40

45

50

55

60

%T

rans

mitt

ance

1000 2000 3000 4000 Wavenumbers (cm-1)

89.84

104.07

149.85

170.04

179.27

196.53210.41

245.73

279.57

333.86

398.39

418.57

455.16

491.75524.55

535.90

552.30

588.89

610.33

629.26

649.44

693.95

42

44

46

48

50

52

54

56

58

60

62

64

%T

rans

mitt

ance

100 200 300 400 500 600 700 Wavenumbers (cm-1)

DBD


124

15 B – Complexo 2


16 B – Complexo 2


603.40

639.41

786.47

851.98

934.42

988.91

1236.30

1322.95

1381.30

1419.73

1568.08

1711.812367.41

2801.57

2936.48

2981.20

3050.87

3101.11

3383.61

3745.98

15

20

25

30

35

40

45

50

55

60

%T

rans

mitt

ance

1000 2000 3000 4000 Wavenumbers (cm-1)

94.11

104.90145.83

159.17

173.12

222.36

277.92

302.23

324.61

351.81

390.50

421.91

458.41

468.65

505.65

517.64

539.67

551.74

578.56

600.49

641.05

671.35

693.70

705.95

45

50

55

60

65

70

75

80

85

90

95

100

%T

rans

mitt

ance

100 200 300 400 500 600 700 Wavenumbers (cm-1)

DBD


125

17 B – Complexo 2

536.35

776.80

904.05

1053.92

1127.68

1209.32

1335.08

1396.72

1455.29

1490.281597.16

1652.70

1723.04

2780.78

3026.96

3113.96

55

60

65

70

75

80

85

90

95

100%

Tra

nsm

ittan

ce

1000 2000 3000 4000 Wavenumbers (cm-1)

Espectro de IR obtida com pastilha de KBr.

18 B – Complexo 3


56.49

88.51

140.14

176.75

199.05

225.97

321.43506.88

541.20

568.54

644.08

660.57

670.17

691.81

40

45

50

55

60

65

70

75

80

85

90

95

100

%T

rans

mitt

ance

100 200 300 400 500 600 700 Wavenumbers (cm-1)

DBD


126

19 B – Complexo 4


20 B – Complexo 4


539.80

796.89

1047.03

1121.21

1179.06

1305.67

1406.95

1467.84

1547.13

1631.08

1710.66

2108.17

2364.89

3206.51

3284.44

3409.82

68

70

72

74

76

78

80

82

84

86

88

90

92

94

96

98

%T

rans

mitt

ance

1000 2000 3000 4000 Wavenumbers (cm-1)

61.18

68.60

106.04

122.71135.26

153.26

200.93

250.54

280.23

322.98

454.01

527.66

555.07

601.82659.05

693.54

35

40

45

50

55

60

65

70

75

80

85

90

%T

rans

mitt

ance

100 200 300 400 500 600 700 Wavenumbers (cm-1)

DBD


127

ANEXO C

Os espectros de massa apresentados neste trabalho foram obtidos no

espectrômetro de massa Bruker Biflex III do Laboratório Van de Graaff do Departamento

de Física da PUC-Rio.

1 C – Composto I

Espectro de massas do composto 1

0 200 400 600 800 10000

500

1000

1500

2000

2500

3000

3500

4000

N

N

N

N

H

N H

C l

246 246

ai

(m /z)

Espetro de M assa do Com posto I

DBD


128

2 C – Composto II


3 C – Composto III


0 200 400 600 800 1000 12000

1000

2000

3000

4000

5000

6000

N

N

N

N

N H

H

269

261

ai

(m/z)

Espectro de massas do composto II

0 200 400 600 800 1000 12000

500

1000

1500

2000

2500

3000

3500

4000 225

ai

(m/z)


DBD


129

4 C – Composto IV

Espectro de massas do composto 4.

5 C – Complexo 1

Espectro de massas do complexo 1

0 200 400 600 800 10000

500

1000

1500

2000

2500

3000

3500

4000

H N

N

N

N

N

H

C F 3280

ai

(m/z)

Espectro de massas do composto IV

0 200 400 600 800 1000 12000

500

1000

1500

2000

2500

3000

3500

N H

N

N

N

N

P t

C l

C l

H3

N

H

C l

268

284 511

429

409

ai

(m/z)

Espectro de massas do complexo 1

DBD


130

6 C – Complexo 2

Espectro de massas do complexo 2.

7 C – Complexo 3

Espectro de massas do complexo 3.

0 2 0 0 4 0 0 6 0 0 8 0 0 1 0 0 0 1 2 0 00

5 0 0

1 0 0 0

1 5 0 0

2 0 0 0

2 5 0 0

3 0 0 0

3 5 0 0

4 0 0 0

N H

N

N

N

N

P t

C l

C l

H 3 N

H

5 2 7

2 6 2

1 4 2

ai

( m / z )

E s p e c t r o d e m a s s a s d o c o m p le x o 2

0 200 400 600 800 10000

500

1000

1500

2000

2500

3000

3500

4000

NH

N

N

N

N

Pt

H3N

H3N

Cl

H

CH3

453

225

267

ai

(m/z)

Espectro de massas (Negativo) docomplexo 3

DBD


131

8 C – Complexo 4

Espectro de massas do composto

0 200 400 600 800 10000

500

1000

1500

2000

HN

N

N

N

N

H

C F 3

290336

603

266

243

ai

(m/z)

Espectro de massas do complexo IV

DBD


132

ANEXO D

Todos os composroa foram analisados no espectrometro de Ressonância

Magnética nuclear (RMN) – Varian, Unity 300 (IME, RJ).

1 D – 6-metilmercaptopurina

RMN- 1H

ppm (f1)0.05.010.015.0

0

5000

8.73

8

8.46

4

3.79

53.

794

2.70

7

0.00

0

1.001.03

0.53

STANDARD 1H OBSERVESTANDARD 1H OBSERVESTANDARD 1H OBSERVESTANDARD 1H OBSERVE6-metilmercaptopurina6-metilmercaptopurina6-metilmercaptopurina6-metilmercaptopurina

N

N

N

N

SCH3

H

DBD


133

RMN 13C

ppm (f1)050100150200

151.

562

143.

182

40.1

3739

.859

39.5

8039

.301

39.0

2238

.743

38.4

64

11.2

88

0.09

013C OBSERVE13C OBSERVE13C OBSERVE13C OBSERVE6-metilmercaptipurina6-metilmercaptipurina6-metilmercaptipurina6-metilmercaptipurina

N

N

N

N

SCH3

H

DBD


134

2 D – 6-metilmesulfonilpurina

RMN-1H

3 D – Composto I

ppm (f1)0.05.010.015.0

11.1

95

9.1

31

8.2

96

2.5

472.

541

2.5

352.

470

0.0

00

1.00

0.24

0.30

STANDARD 1H OBSERVESTANDARD 1H OBSERVESTANDARD 1H OBSERVESTANDARD 1H OBSERVE6-Metilsulfonilpurina6-Metilsulfonilpurina6-Metilsulfonilpurina6-Metilsulfonilpurina

N

N

N

N

S

H

O

CH3

O

DBD


135

RMN-13C

ppm (f1)050100150200

153.

717

149.

984

139.

375

116.

230

40.3

5540

.077

39.7

9939

.520

39.2

4238

.963

38.6

8513C OBSERVE13C OBSERVE13C OBSERVE13C OBSERVE

6-metilsulfonilpurina6-metilsulfonilpurina6-metilsulfonilpurina6-metilsulfonilpurina

N

N

N

N

S

H

O

C H3

O

DBD


136

RMN- 1H

ppm (f1)0.05.010.0

0

1000

2000

3000

4000

5000

10.

732

10.

723

10.

720

10.

719

10.

717

10.

716

10.

714

10.

701

8.5

968

.556

8.2

028

.195

8.1

887

.867

7.8

647

.860

7.8

397

.837

7.8

33

7.4

217

.394

7.3

677

.159

7.1

577

.153

7.1

507

.133

7.1

307

.126

2.5

062

.500

2.4

94

1.00

1.28

1.50

1.40

1.39

3.04

M-cloro-purina- RMN-HM-cloro-purina- RMN-HM-cloro-purina- RMN-HM-cloro-purina- RMN-H

N

N

N

N

H

N H

1

2

34

5 7

8

9

Cl

1 '

2'

6

3'

4'

5 '

6'

1'

DBD


137

RMN-13C

DBD


138

3 D-Composto II

RMN-1H

ppm (f1)050100150200

151

.111

149

.951

144

.656

134

.159

127

.775

126

.707

125

.446

123

.591

122

.695

122

.308

115

.346

107

.406

40.7

37

40.0

64

39.7

86

39.5

09

39.2

31

38.9


composto 2composto 2composto 2composto 2

N

N

N

N

N H

H

DBD


139

RMN- 13C

ppm (f1)050100150200

0

5000

10000

15000151.

111

149.

951

144.

656

134.

159

127.

775

126.

707

125.

446

123.

591

122.

308

115.

346

107.

406

40.7

3740

.064

39.7

86

39.5

0939

.231

38.9


6- (naftlilamino )-Purina6- (naftlilamino )-Purina6- (naftlilamino )-Purina6- (naftlilamino )-Purina

NH

N

N

N

N

H

DBD


140

4 D- Composto III

RMN-1H

ppm (f1)0.05.010.0

0

5000

8.9

26

8.3

81

8.3

03

7.8

34

7.8

06

7.7

80

7.4

11

7.3

84

7.3

82

7.1

71

7.1

63

7.1

35

3.5

53

2.5

23

2.5

18

2.5

05

2.5

04

2.4

10

2.3

71

2.2

88

1.00

1.510.50

1.51

0.04

0.27

0.28

STANDARD 1H OBSERVESTANDARD 1H OBSERVESTANDARD 1H OBSERVESTANDARD 1H OBSERVEcomposto 3composto 3composto 3composto 3

H N

N

N

N

N

H

C H3

DBD


141

RMN-13C

ppm (f1)050100150200

0

5000

10000

15000

20000

25000152.

024

142.

119

141.

147

137.

583

132.

359

130.

602

129.

801

129.

578

123.

120

121.

488

46.2

84

21.7

1121

.178

13C OBSERVE13C OBSERVE13C OBSERVE13C OBSERVEcompoto IIIcompoto IIIcompoto IIIcompoto III

HN

N

N

N

N

H

CH3

DBD


142

5 D- Composto IV

RMN-1H

ppm (f1)0.05.010.015.0

11.

162

8.5

828

.532

8.3

84

8.1

568

.150

8.1

488

.122

8.1

208

.118

8.1

167

.622

7.5

967

.569

7.4

397

.437

7.4

11

7.3

51

7.0

907

.086

7.0

847

.081

7.0

777

.075

7.0

691

.00

0.8

70

.57

0.3

7

0.3

20

.31

0.6

8

STANDARD 1H OBSERVESTANDARD 1H OBSERVESTANDARD 1H OBSERVESTANDARD 1H OBSERVE

COMPOSTO IVCOMPOSTO IVCOMPOSTO IVCOMPOSTO IV

N

N

N

N

H

NH

1

2

34

5 7

8

9

CF3

1'

2'

6

3'

4'

5'

6'

1'

7'

DBD


143

RMN-13C

ppm (f1)050100150200

151.

246

150.

802

150.

592

145.

009

142.

874

142.

833

140.

376

130

.875

130.

715

130.

550

130.

313

129.

896

125.

196

121.

108

120.

328

120.

283

117.

757

117.

718

117.

358

40.9

6940

.690

40.4

1240

.134

39.8

5539

.577

39.2

9813C OBSERVE13C OBSERVE13C OBSERVE13C OBSERVE13C OBSERVE13C OBSERVE13C OBSERVE13C OBSERVEcomposto IVcomposto IVcomposto IVcomposto IV

H N

N

N

N

N

H

C F 3

DBD


9 REFERÊNCIAS - dbd.puc-rio.br · Med. Vet. Entomol. , v.14, p. 109-122, 2001. ... Brasileira de...

Documents

Transcript of 9 REFERÊNCIAS - dbd.puc-rio.br · Med. Vet. Entomol. , v.14, p. 109-122, 2001. ... Brasileira de...